SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 2
    Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 47289.
  • 3
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 4
    Lampertico P, Del Ninno E, Viganò M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 75663.
  • 5
    Oliveri F, Puoti M, Santantonio T, et al. Efficacy and impact on disease progression of IFN treatment in patients with HBeAg-negative chronic hepatitis B: a long term Italian multicenter A. I.S.F. cohort study. Hepatology 2005; 42: 577A.
  • 6
    Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 4758.
  • 7
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 33552.
  • 8
    McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24: S1721.
  • 9
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 30613.
  • 10
    Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 26370.
  • 11
    Di Marco V, Lo Iacono O, Cammà C, et al. The long term course of chronic hepatitis B. Hepatology 1999; 30: 25764.
  • 12
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15213.
  • 13
    Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 88391.
  • 14
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 15
    Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 216979.
  • 16
    Marcellin P, Piratvisuth T, Brunetto M, et al. Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a±lamivudine: results of 5-year posttreatment follow up. J Hepatol 2009; 50: S336.
  • 17
    Villa E, Lei B, Taliani G, et al. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study. Antivir Ther 2009; 14: 10817.
  • 18
    Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799804.
  • 19
    Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699705.
  • 20
    Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther 2009; 14: 116574.
  • 21
    Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 17629.
  • 22
    Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis virus DNA without hepatitits B e antigen in serum. Hepatology 1997; 26: 16215.
  • 23
    Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 271823.
    Direct Link:
  • 24
    Lampertico P, Viganò M, Di Costanzo GG, et al. Extended (2 years) treatment with peginterferon alfa-2a [40KD] improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010; 52 (Suppl. 1): S45.
  • 25
    Farci P, Marcellin P, Lu ZM, et al. On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon alpha-2a (40 kDa) (Pegasys). J Hepatol 2005; 42 (Suppl. 2): 175A.
  • 26
    Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 11517.
  • 27
    Marcellin P, Brunetto M, Bonino F, et al. In patients with HBeAg-negative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology 2008; 48 (Suppl. 1): 718.
  • 28
    Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 114150.
  • 29
    Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 45461.
  • 30
    Rijckborst V, Hansen BE, Ferenci F, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy. Hepatology 2010; 52(Suppl): 557A.